Kisspeptin is the notable exception, dosed at 1 to 10 mcg/kg in clinical research
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial
That said, Novo Nordisk and Eli Lilly aren't exactly sitting around doing nothing, so more GLP-1 developments are likely from this pair, as well
Table of Contents How GLP-1 Medications Affect Bowel Movements Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications increasingly prescribed for type 2 diabetes management and weight loss
While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
I think there is considerable potential for this drug (and class) as a treatment for obstructive sleep apnea
